SCHEMBL6412434

SCHEMBL6412434

CNCc1ccccc1OCc1ccc(F)cc1

nearest known ligand 0.97

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.97
PKM P14618 1/20 0.97
MCL1 Q07820 1/20 0.68
TRPV6 Q9H1D0 1/20 0.67
LMNA P02545 5/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HTT P42858 2/20 0.58
MAPK1 P28482 1/20 0.56
PLA2G1B P04054 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SLC6A2 P23975 1/20 0.51
SLC6A3 Q01959 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13948892 0.88 ALDH1A1 (0.77) ALDH1A1PKMMCL1TRPV6LMNA
SCHEMBL31504076 0.84 TRPV6 (0.71) ALDH1A1PKMMCL1TRPV6LMNA
SCHEMBL8283688 0.81 ALDH1A1 (0.67) ALDH1A1PKMTRPV6LMNASMN1; SMN2
SCHEMBL5397561 0.80 ALDH1A1 (0.65) ALDH1A1PKMTRPV6LMNASMN1; SMN2
SCHEMBL32670477 0.78 ALDH1A1 (0.62) ALDH1A1PKMTRPV6LMNASMN1; SMN2
SCHEMBL15444414 0.78 MCL1 (0.63) ALDH1A1PKMMCL1MAPK1GAA
SCHEMBL6419998 0.78 SLC6A4 (0.64) ALDH1A1PKMMCL1LMNAMAPK1
SCHEMBL20852556 0.77 SLC6A4 (0.73) ALDH1A1PKMMCL1SLC6A2SLC6A3
SCHEMBL29227214 0.76 PLA2G1B (0.60) ALDH1A1PKMTRPV6LMNASMN1; SMN2
SCHEMBL1254288 0.75 ALDH1A1 (0.60) ALDH1A1PKMMCL1MAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 ALDH1A1 1020/4885PKM 4021/4885MCL1 1015/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 ALDH1A1 239/4885PKM 3996/4885MCL1 469/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 ALDH1A1 239/4885PKM 3996/4885MCL1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.